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Abstract 
We report a straightforward and efficient synthetic strategy for the synthesis of 
three model glycine-arginine-glycine-aspartic-glycine (GRGDG) conjugates based on 
derivatives of NOTA and of their Ga(III) complexes targeted to the integrin 3 
receptor. 71Ga NMR spectroscopy showed that the Ga(III)-labeled conjugates are highly 
stable in aqueous solution. The 67Ga-labeled conjugates proved to have high kinetic 
stability and showed a weak but specific binding to the receptors in a U87MG-
glioblastoma cell line. 
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Gallium has three radioisotopes of interest for medical imaging, 67Ga (t1/2 = 3.25 
days), 66Ga (t1/2 = 9.5 h) and 68Ga (t1/2 = 68 min). The first one, a γ emitter, can be used 
in γ-scintigraphy, while the others, being β+ emitters, are appropriate for positron 
emission tomography (PET). 68Ga is a very attractive radionuclide for PET, as it can be 
produced in situ from a 68Ge generator, allowing easy routine manufacture in the 
hospital facilities comparable to what happens with the 99Mo/99mTc-generator. Gallium-
based radiopharmaceuticals preparation is easy and fast, contrarily to the preparation of 
18F or 11C covalently labeled PET agents, leading to a minimum loss of activity.1-2 
The most common chelators for Ga(III) are hexadentate1,3-17 and, among them, 
triaza macrocycles are specially suitable due to their high conformational and size 
selectivities, allowing a good fit of the relatively small cation in the macrocyclic cavity. 
Such is the case of 1,4,7-triazacyclononane-N,N´,N´´-triacetic acid (NOTA) 5, which 
forms highly stable chelates and allows a faster incorporation of Ga(III) at lower 
temperatures than 1,4,7,10-tetraazacyclododecane- N,N´,N´´,N’’’-tetraacetic acid 
(DOTA), its tetraaza analog.18 
Recently we reported the synthesis and study of micelles forming Ga(III) 
chelates of NOTA-based ligands with a variable size α-alkyl chain in one of the acetate 
arms.4 The synthetic route of these ligands is compatible with their conjugation to 
amine-containing biomolecules, rendering them bifunctional chelators. Bifunctional 
chelators are molecules displaying a targeting vector with high affinity and selectivity 
for a specific receptor and a metal ion that can be used for diagnosis or therapy.19 
Amongst biomolecules, peptides have shown to be the most effective targeting moieties 
known for cellular receptors, drug delivery, molecular imaging and radiotherapeutic 
applications.20-23 The compatibility with peptide synthesis requires that bifunctional 
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chelators, often bearing carboxylic acid groups, offer the possibility of orthogonal 
protection.24  
The arginine-glycine-aspartic (RGD) peptide sequence has emerged as one of 
the most efficient epitopes for targeting the integrin3 receptor. Integrin 3 
receptor is a transmembrane protein that acts as a receptor for extracellular matrix 
proteins with RGD tripeptide sequence.25-26 This integrin is highly expressed in active 
endothelial cells of the neovasculature of various tumors and it has been demonstrated 
that it is overexpressed in both endothelial cells and tumor cells in human breast cancer 
xenografts.27 The integrin 3 receptor expression correlates well with tumor 
progression and invasiveness of melanoma, glioma, ovarian and breast cancers.25,27 Due 
to the restricted expression of 3 in tumors, this integrin is considered an adequate 
molecular target for tumor targeting.28-30  
In this paper we report an efficient synthetic route for coupling NOTA-based 
pro-chelators to peptides. As proof-of-concept we have used as a model peptide a linear 
glycine-argine-glycine-aspartic-glycine (GRGDG) pentapeptide. Three conjugates were 
obtained (Fig. 1) and their radiolabeling with 67Ga has been characterized; stability and 
hydrophilicity studies have been performed. In vitro studies with a human glioblastoma 
cell line complemented this work. 
The NOTA conjugates were prepared according to the strategy presented in 
Scheme 1. NOTA-based pro-chelators (1a-c) display one acetate pendant arm with a -
alkyl chain of variable size [1,4,7-triazacyclononane-N-hexanamide-(glycine-arginine-
glycine-aspartic-glycine)-N’,N’’-diacetic acid (NOTAC6-GRGDG) 1a, 1,4,7-
triazacyclononane-N-octanamide-(glycine-arginine-glycine-aspartic-glycine)-N’,N’’-
diacetic acid (NOTAC8-GRGDG) 1b, 1,4,7-triazacyclononane-N-decanamide-(glycine-
arginine-glycine-aspartic-glycine)-N’,N’’-diacetic acid (NOTAC10-GRGDG) 1c] and 
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were synthesized following a procedure previously developed by us which involves an 
orthogonal protection strategy for the carboxylic moieties.4 The protecting groups used 
were the benzhydryl ester, cleaved by Pd catalyzed hydrogenolysis, and the tert-butyl 
ester, cleaved in acid. After cleavage of the single benzhydryl ester, the pro-chelators 
2a-c were ready for coupling to the GRGDG peptide. The model GRGDG peptide was 
prepared by standard solid phase peptide synthesis (SPPS) using a 
fluorenylmethoxycarbonyl (Fmoc) protocol and a 2-chlorotrityl chloride resin. For side-
chain protection the 2,2,4,6,7-pentamethyl dihydrobenzofuran-5-sulfonyl (Pbf) group 
for arginine and the tert-butyl (tBu) group for aspartic acid were used. Coupling 
reactions were performed with diisopropylcarbodiimida (DIC) and 1-
hydroxybenzotriazole (HOBt). The coupling of the NOTA pro-chelators (2a-c) to the 
GRGDG peptide were carried out in solid phase using O-benzotriazole-N,N,N’,N’-
tetramethyl-uronium-hexafluoro-phosphate (HBTU) and HOBt (Scheme 1). After 
cleavage from the resin and removal of the protecting groups, the peptide conjugates 
NOTAC6-GRGDG (3a), NOTAC8-GRGDG (3b), NOTAC10-GRGDG (3c) were 
obtained with good yields (Scheme 1).31 
 The 71Ga NMR spectrum of the Ga(III) complex of NOTAC6-GRGDG in 
aqueous solution (pH 7) shows a signal at 166 ppm (v1/2 = 454 Hz) in conformity with 
an octahedral or pseudo-octahedral coordination geometry, comparable to what has 
been previously observed by us for [Ga(NOTAC6)].4 It is interesting to verify that the 
replacement of a carboxylate oxygen by an amide carbonyl oxygen in the conjugate 
does not affect the coordination geometry of Ga(III). The 71Ga NMR signal was 
observed unchanged over a time period of 2 months, reflecting the high stability of the 
chelate in aqueous solution. 
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NOTAC6-GRGDG and NOTAC8-GRGDG were efficiently labeled with 
67Ga(III) using HEPES buffer (pH 3.6, 0.1 M) and heating at 95ºC for 1 h. The 67Ga 
source was gallium citrate. The radiochemical purity control was performed by radio-
HPLC showing a single peak with rt = 10.1 min for [67Ga]NOTAC6-GRGDG and a 
single peak with rt = 10.5 min for [67Ga]NOTAC8-GRGDG. In both cases the labeling 
yields were > 80%. 
Stability studies have demonstrated that [67Ga]NOTAC8-GRGDG does not 
release the radiometal, even under extreme conditions (a 104 fold molar excess of 
DTPA) at least during the period of time evaluated, 24 h. The HPLC results have shown 
that no radiolysis breakdown products were formed. The stability observed for 
[67Ga]NOTAC8-GRGDG is in agreement with the thermodynamic stability of most of 
the Ga(III) triaza complexes.3,5,9,13,15-16,32 
The lipophilicity of the chelates (logP values) was determined measuring the 
octanol/water partition coefficients of [67Ga]NOTAC6-GRGDG and [67Ga]NOTAC8-
GRGDG which demonstrated that these chelates are moderately hydrophilic (logP = - 
2.66 and logP = - 1.30, respectively). These results are in accordance with our previous 
studies and correlate with the different lengths of the -alkyl side chain.4 
The human glioblastoma (U87MG) cell line is known to overexpress the3 
receptor.33 In this experiment, we evaluated the interaction of [67Ga]NOTAC6-GRGDG 
with the 3 receptors. Echistatin, known as the most potent integrin receptor 
blocker,34 was added to evaluate the specificity of the process. The cells were incubated 
with [67Ga]NOTAC6-GRGDG for 60 min at 37 °C. After 60 minutes the cells were 
washed and treated with an acid buffer to remove the tracer bounded to the cell surface, 
and then detached from the plates. The radioactivity inside the cells together with the 
activity associated to the cell membranes (removed by acid wash) were measured in a  
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well counter. The results of this experiment are the average of three independent 
measurements and are expressed as percentage of added activity per million of cells 
(Table 1).  
 After 1 h, the activity retained in the cells was somewhat low, 0.24 ± 0.05 (% 
added activity per million of cells), suggesting a low binding affinity of the 
[67Ga]NOTAC6-GRGDG conjugate towards the integrin receptor, in accordance to 
what is known for linear RGD peptides.29 This value was reduced to 0.14 ± 0.01 when 
the cells were treated with echistatin indicating that, despite the low affinity of the 
bioconjugate, we are facing a specific process.  
In conclusion, we synthesized three NOTA-based conjugates of a model 
GRGDG peptide adequate for radiolabeling with Ga(III), which are targeted to the 
integrin 3 receptor . The synthetic route that was used makes use of an orthogonal 
protection strategy that may also be efficiently applied to DOTA-based chelators (referir 
artigo do André?) and to other peptides.35 Potentially, the presence of a pendant α–alkyl 
chain in the chelator moiety has an effect on the pharmacokinetic properties of the 
correspondent Ga(III) labeled conjugates, and these might be tuned in accordance to the 
number of carbon atoms of the chain. Despite the fact that one of the triaza carboxylic 
groups is used for conjugation to the peptide, through amide bond formation, the Ga(III) 
complex in the conjugate remains hexacoordinated with an octahedral or pseudo-
octahedral geometry, presenting high stability in aqueous solution as shown by 71Ga 
NMR and competition experiments with DTPA.  
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Table 1 – [67Ga]NOTAC6-GRGDG internalisation at 1h in the U87MG cell line with 
and without receptor blocker (echistatin). The results are express as percentage of added 
activity per million of cells. 
Condition Cell surface Internalized 
[67Ga]NOTAC6-GRGDG 2.43 ± 0.16 0.24 ± 0.05 
[67Ga]NOTAC6-GRGDG and Echistatin  1.03 ± 0.03 0.14 ± 0.01 
 
 
Figure 1 – Structure of the GRGDG conjugates. 
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Scheme 1 – Synthesis of the NOTA-GRGDG conjugates. (a) EtOH, CHO2H.NH3, 10% 
Pd/C, N2, ; (b) i) DMF, HBTU, HOBt; ii) Et3N; (c) i) AcOH/TFE/DCM (1:1:3); ii) 
TFA. 
